Premium
Pharmacokinetics of Quinapril in Children: Assessment during Substitution for Chronic Angiotensin‐Converting Enzyme Inhibitor Treatment
Author(s) -
Blumer Jeffrey L.,
Daniels Stephen R.,
Dreyer William J.,
Batisky Donald,
Walson Philip D.,
Roman Doina,
Ouellet Daniele
Publication year - 2003
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270002239820
Subject(s) - quinapril , pharmacokinetics , cmax , angiotensin converting enzyme , ace inhibitor , body surface area , active metabolite , dosing , medicine , pharmacology , chemistry , blood pressure
Quinapril pharmacokinetics were studied in infants and children using a novel study design that allowed substitution of quinapril for one dose of the current chronic angiotensin‐converting enzyme (ACE) inhibitor treatment. A total of 24 patients ranging in age from 2.5 to 82 months who were receiving an ACE inhibitor held their usual treatment on the study day and received a 0.2‐mg/kg dose of quinapril syrup. Blood samples were collected through 24 hours postdose, and plasma was analyzed for quinapril and its active metabolite, quinaprilat. Quinapril was rapidly converted to quinaprilat. Quinaprilat concentrations generally peaked 1 to 2 hours postdose and declined with a mean half‐life of 2.30 hours. Dosing on a mg/kg basis resulted in quinaprilat AUC and C max values that were generally comparable across the age range of patients in this study. The overall mean AUC 0–∞ was 993 ng•h/mL (range: 533–1523), and mean C max was 260 ng/mL (range: 70.0–445.5). Quinaprilat CL/F correlated well with body size (body surface area or weight) and creatinine clearance (mL/min). Pharmacokinetic results after a 0.2‐mg/kg dose in infants and children are comparable to those observed following a 10‐mg dose in adults.